COVID-19 Telehealth
Free telehealth for COVID-19 treatment with Paxlovid
Telehealth is a quick and easy way to see if Paxlovid, a COVID-19 treatment pill, is right for you.
Table of Contents
Easy, free care for COVID-19
Request a telehealth consultation with a clinician to see if Paxlovid or Molnupiravir is right for you. Paxlovid and Molnupiravir are pills that can help treat COVID-19. If it's right for you, you can get your prescription through home delivery or pharmacy pickup. There is no cost to you for this service through the partnership with the State of New Hampshire.
You'll have a telehealth consultation with a licensed clinician
-
If you're eligible, you'll have a consultation with a clinician to see if antiviral treatment is right for you. You can select a video or phone call.
-
For a video consultation, you’ll only need a smartphone or computer with video capabilities. No special software is required.
-
Your consultation will be confidential in accordance with applicable medical privacy laws. You can view our consent for healthcare services.
Contact
On-site Medical Services
Support Team Phone
800-816-5803
Available 8 a.m. - 6 p.m. EST
Weekends 9 a.m. - 5 p.m. EST
Live Help On-line
Available 8 a.m. - 6 p.m. EST
Weekends 9 a.m. - 5 p.m. EST
You'll need to provide some health information
-
You’ll need to have tested positive for COVID-19 and had your first symptom in the last 5 days. You won’t need to upload a positive COVID-19 test.
-
If you have a kidney disease, you’ll need to upload a copy of lab results from the last 3 months.
Available 7 days a week including holidays
What is Paxlovid?
-
Paxlovid has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 88 lbs) with positive results of direct SARS CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
-
If Paxlovid is right for you, treatment should start as soon as possible after COVID-19 diagnosis and your first symptom in the last 5 days. Paxlovid is not for people who have a history of allergy to nirmatrelvir or ritonavir or other components of these drugs, and it is not for people taking certain other drugs. Paxlovid may cause side effects, some of which may be serious and unexpected. Learn more about Paxlovid on the manufacturer’s website, and review the patient and healthcare provider fact sheets for more information.
-
The emergency use of Paxlovid is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization revoked sooner.
Symptoms
COVID-19 is a respiratory disease, caused by a novel (or new) coronavirus that emerged in late 2019. Reported illness ranges from mild symptoms to severe illness and death for confirmed COVID-19 cases.
Symptoms of infection may appear 2-14 days after exposure to the virus and may include:
-
Fever or chills
-
Cough
-
Shortness of breath or difficulty breathing
-
Fatigue
-
Muscle or body aches
-
Headache
-
New loss of sense of taste or smell
-
Sore throat
-
Congestion or runny nose
-
Nausea or vomiting
-
Diarrhea
-
In elderly, chronically ill, or debilitated individuals such as residents of a long-term care facility, symptoms of COVID-19 may be subtle such as alterations in mental status or in blood glucose control
-
However, it’s possible for people with COVID-19 to spread the virus to others up to 48 hours before they have symptoms. Visit the CDC's resource on symptoms for more information.
If you develop symptoms of COVID-19, even if they are mild, please contact your healthcare provider and a test site near you to schedule a test.
On-site Medical Services, LLC. is a privately held company. The COVID-19 vaccination program is financed under a contract with the State of New Hampshire, Department of Health and Human Services, with funds provided in part by the State of New Hampshire and/or such other funding sources as were available or required, e.g., the United States Department of Health and Human Services.